[1] M. G. Fowler et al., “Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.,” N. Engl. J. Med., vol. 375, no. 18, pp. 1726–1737, 2016.
[2] F. Dabis and E. R. Ekpini, “HIV-1/AIDS and maternal and child health in Africa.,” Lancet (London, England), vol. 359, no. 9323, pp. 2097–104, Jun. 2002.
[3] UNAIDS, “Global HIV & AIDS statistics — 2019 fact sheet,” 2019. [Online]. Available: https://www.unaids.org/en/resources/fact-sheet. [Accessed: 23-Oct-2019].
[4] S. M. Stricker et al., “Retention in care and adherence to ART are critical elements of HIV care interventions.,” AIDS Behav., vol. 18 Suppl 5, no. S5, pp. S465-75, Oct. 2014.
[5] P. M. Barker, W. Mphatswe, and N. Rollins, “Antiretroviral Drugs in the Cupboard Are Not Enough: The Impact of Health Systems’ Performance on Mother-to-Child Transmission of HIV.,” J.Acquir.Immune.Defic.Syndr., vol. 00, no. 0, pp. 1–4, 2010.
[6] E. L. Sibanda, I. V.D. Weller, J. G. Hakim, and F. M. Cowan, “The magnitude of loss to follow-up of HIV-exposed infants along the prevention of mother-to-child HIV transmission continuum of care,” Aids, vol. 27, no. 17, pp. 2787–2797, 2013.
[7] M. P. Fox et al., “2015 Progress Report on the Global Plan,” PLoS One, vol. 11, no. 1, pp. 18–20, 2016.
[8] C. Psaros, J. E. Remmert, D. R. Bangsberg, S. A. Safren, and J. A. Smit, “Adherence to HIV care after pregnancy among women in sub-Saharan Africa: falling off the cliff of the treatment cascade.,” Curr. HIV/AIDS Rep., vol. 12, no. 1, pp. 1–5, Mar. 2015.
[9] B. A. Knettel et al., “Retention in HIV Care During Pregnancy and the Postpartum Period in the Option B+ Era,” JAIDS J. Acquir. Immune Defic. Syndr., vol. 77, no. 5, pp. 427–438, Apr. 2018.
[10] S. Gumede-Moyo, S. Filteau, T. Munthali, J. Todd, and P. Musonda, “Implementation effectiveness of revised (post-2010) World Health Organization guidelines on prevention of mother-to-child transmission of HIV using routinely collected data in sub-Saharan Africa: A systematic literature review,” Medicine (Baltimore)., vol. 96, no. 40, pp. 1–12, 2017.
[11] W. M. Bezabhe, L. Chalmers, L. R. Bereznicki, and G. M. Peterson, “Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-Analysis.,” Medicine (Baltimore)., vol. 95, no. 15, p. e3361, Apr. 2016.
[12] C. L. Wallis, C. Godfrey, J. E. Fitzgibbon, and J. W. Mellors, “Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries,” J. Infect. Dis., vol. 216, no. suppl_9, pp. S851–S856, Dec. 2017.
[13] S. Bertagnolio et al., “Determinants of HIV drug resistance and public health implications in low- and middle-income countries,” Antivir. Ther., vol. 17, no. 6, pp. 941–953, 2012.
[14] E. Lathrop, D. J. Jamieson, and I. Danel, “HIV and maternal mortality.,” Int. J. Gynaecol. Obstet., vol. 127, no. 2, pp. 213–5, Nov. 2014.
[15] S. Linnemayr and T. Rice, “Insights From Behavioral Economics to Design More Effective Incentives for Improving Chronic Health Behaviors, With an Application to Adherence to Antiretrovirals,” JAIDS J. Acquir. Immune Defic. Syndr., vol. 72, no. 2, pp. e50–e52, Jun. 2016.
[16] N. K. Taylor and A. M. Buttenheim, “Improving utilization of and retention in PMTCT services: Can behavioral economics help?,” BMC Health Serv. Res., vol. 13, no. 1, p. 406, Dec. 2013.
[17] I. V Bassett et al., “Financial incentives to improve progression through the HIV treatment cascade,” Curr Opin HIV AIDS., vol. 10, no. 6, pp. 451–463, 2016.
[18] D. Operario, C. C. Kuo, S. G. Sosa-Rubí, and O. Gálarraga, “Conditional Economic Incentives for Reducing HIV Risk Behaviors: Integration of Psychology and Behavioral Economics,” Heal. Psychol., vol. 32, no. 9, pp. 932–940, 2013.
[19] A. Fiszbein and N. R. Schady, “Conditional cash transfers: A World Bank Policy Report,” Washington, D.C., 2009.
[20] S. Frederick, G. Loewenstein, and T. O ’donoghue^, “Time Discounting and Time Preference: A Critical Review,” foumal ofEconimiic Lit., 2002.
[21] M. Swann, “AIDS Care Psychological and Socio-medical Aspects of AIDS/HIV Economic strengthening for retention in HIV care and adherence to antiretroviral therapy: a review of the evidence Economic strengthening for retention in HIV care and adherence to antiretrovir,” AIDS Care - Psychol. Socio-Medical Asp. AIDS/HIV, vol. 30, no. 3, pp. 99–125, 2018.
[22] S. I. McCoy et al., “Cash vs. food assistance to improve adherence to antiretroviral therapy among HIV-infected adults in Tanzania,” Aids, vol. 31, no. 6, pp. 815–825, 2017.
[23] M. Yotebieng et al., “Conditional Cash Transfers to Increase Retention in PMTCT Care, Antiretroviral Adherence, and Postpartum Virological Suppression,” JAIDS J. Acquir. Immune Defic. Syndr., 2016.
[24] S. S. Solomon et al., “Voucher Incentives Improve Linkage to and Retention in Care Among HIV-Infected Drug Users in Chennai, India,” Clin. Infect. Dis., vol. 59, no. 4, pp. 589–595, Aug. 2014.
[25] N. M. Petry, C. J. Rash, S. Byrne, S. Ashraf, and W. B. White, “Financial reinforcers for improving medication adherence: findings from a meta-analysis.,” Am. J. Med., vol. 125, no. 9, pp. 888–96, Sep. 2012.
[26] M. I. Rosen et al., “Improved Adherence with Contingency Management,” AIDS Patient Care STDS, vol. 21, no. 1, pp. 30–40, Jan. 2007.
[27] J. L. Sorensen et al., “Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial.,” Drug Alcohol Depend., vol. 88, no. 1, pp. 54–63, Apr. 2007.
[28] M. O. Rigsby et al., “Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention.,” J. Gen. Intern. Med., vol. 15, no. 12, pp. 841–7, Dec. 2000.
[29] O. Galárraga, B. L. Genberg, R. A. Martin, M. B. Laws, and I. B. Wilson, “Conditional economic incentives to improve HIV treatment adherence: literature review and theoretical considerations,” AIDS Behav., vol. 17, no. 7, pp. 2283–2292, 2013.
[30] M. Yotebieng et al., “Conditional cash transfers increase uptake of and retention in PMTCT care: A randomized controlled trial,” Lancet HIV, vol. 3, no. 2, pp. e85–e93, 2016.
[31] K. Kroenke, R. L. Spitzer, and J. B. W. Williams, “The PHQ-9: Validity of a brief depression severity measure,” J. Gen. Intern. Med., vol. 16, no. 9, pp. 606–613, 2001.
[32] G. Bickel, M. Nord, C. Price, W. Hamilton, and J. Cook, “Guide to Measuring Household Food Security,” USDA Econ. Res. Serv., pp. 1–82, 2000.
[33] L.-W. Chao, H. Szrek, N. S. Pereira, and M. V Pauly, “Time preference and its relationship with age, health, and survival probability.,” Judgm. Decis. Mak., vol. 4, no. 1, pp. 1–19, Feb. 2009.
[34] J. Haushofer and E. Fehr, “On the psychology of poverty,” Science, pp. 862–867, 2014.
[35] P. D. Sozou and R. M. Seymour, “Augmented discounting: interaction between ageing and time-preference behaviour,” Proc. R. Soc. B Biol. Sci., vol. 270, no. 1519, pp. 1047–1053, May 2003.
[36] A. Ahmed, “Rationality and Future Discounting,” Topoi, vol. 1, no. 0123456789, pp. 1–12.
[37] F. G. Moeller, D. M. Dougherty, E. S. Barratt, J. M. Schmitz, A. C. Swann, and J. Grabowski, “The impact of impulsivity on cocaine use and retention in treatment.,” J. Subst. Abuse Treat., vol. 21, no. 4, pp. 193–8, Dec. 2001.
[38] L. Stevens, A. Verdejo-García, A. E. Goudriaan, H. Roeyers, G. Dom, and W. Vanderplasschen, “Impulsivity as a vulnerability factor for poor addiction treatment outcomes: A review of neurocognitive findings among individuals with substance use disorders,” J. Subst. Abuse Treat., vol. 47, no. 1, pp. 58–72, Jul. 2014.
[39] S. Linnemayr and C. Stecher, “Behavioral Economics Matters for HIV Research: The Impact of Behavioral Biases on Adherence to Antiretrovirals (ARVs).,” AIDS Behav., vol. 19, no. 11, pp. 2069–75, Nov. 2015.
[40] H. Thirumurthy et al., “Time Preferences Predict Mortality among HIV-Infected Adults Receiving Antiretroviral Therapy in Kenya.,” PLoS One, vol. 10, no. 12, p. e0145245, 2015.
[41] E. Hamilton et al., “Using the PMTCT Cascade to Accelerate Achievement of the Global Plan Goals,” JAIDS J. Acquir. Immune Defic. Syndr., vol. 75, pp. S27–S35, 2017.
[42] P. M. Musumari, M. D. Feldman, T. Techasrivichien, E. Wouters, M. Ono-Kihara, and M. Kihara, “‘If I have nothing to eat, I get angry and push the pills bottle away from me’: A qualitative study of patient determinants of adherence to antiretroviral therapy in the Democratic Republic of Congo,” AIDS Care, vol. 25, no. 10, pp. 1271–1277, Oct. 2013.
[43] B. Mupenda et al., “Terms Used for People Living With HIV in the Democratic Republic of the Congo,” Qual. Health Res., vol. 24, no. 2, pp. 209–216, Feb. 2014.
[44] M. Yotebieng et al., “Conditional cash transfers improve retention in PMTCT services by mitigating the negative effect of not having money to come to the clinic,” JAIDS J. Acquir. Immune Defic. Syndr., vol. 74, no. 2, p. 1, 2016.
[45] S. Burks, J. Carpenter, L. Götte, and A. Rustichini, “Which measures of time preference best predict outcomes: Evidence from a large-scale field experiment,” J. Econ. Behav. …, no. 5808, 2012.
[46] D. Laibson, “Golden Eggs and Hyperbolic Discounting,” Q. J. Econ., vol. 112, no. 2, pp. 443–477, 1997.
[47] T. O’Donoghue and M. Rabin, “Doing It Now or Later,” Am. Econ. Rev., vol. 89, no. 1, pp. 103–124, Mar. 1999.
[48] K. J. Rothman, S. Greenland, and T. L. Lash, Modern epidemiology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008.
[49] K. Esopo et al., “Measuring self-efficacy, executive function, and temporal discounting in Kenya,” Behav. Res. Ther., vol. 101, pp. 30–45, Feb. 2018.
[50] L. Carvalho, S. Meier, and S. Wang, “Poverty and Economic Decision-Making: Evidence from Changes in Financial Resources at Payday.,” Am. Econ. Rev., 2014.
[51] R. Cassidy, G. Rasool, T. Khan, and H. Zaman, “Are the poor really so present-biased? Experimental evidence from Pakistan,” Inst. Fisc. Stud., vol. 18, no. 24, 2017.
[52] F. C. Mukumbang, S. Van Belle, B. Marchal, and B. van Wyk, “Exploring ‘generative mechanisms’ of the antiretroviral adherence club intervention using the realist approach: a scoping review of research-based antiretroviral treatment adherence theories,” BMC Public Health, vol. 17, no. 1, p. 385, Dec. 2017.
[53] National Institutes of Health (NIH), “Science of Behavior Change,” 2018. [Online]. Available: https://commonfund.nih.gov/behaviorchange. [Accessed: 10-Nov-2018].